Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, recently announced that its President and Chief […]
Soligenix Initiates Phase 3 Trial of Dusquetide for Oral Mucositis in Head & Neck Cancer Patients
Soligenix’s self-described “DOM–INNATE” study has initiated patient enrollment. The late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced that patient […]
BIO-CEO Wraps Up 19th Annual Investor Conference
Now in its 19th year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. With a mission to support industry-wide […]
Stephen Chang – New York Stem Cell Foundation
As Senior Vice President of Strategic Initiatives at the New York Stem Cell Foundation, Stephen Chang is one of the leading experts in gene therapy and neurodegenerative. Dr. Chang speaks with Brett […]
Bioinformatics Special Report, Part I: Where Does Biotechnology Data Come From?
Bioinformatics is the field of science involved with using computational methods to convert raw biological data into meaningful biological paradigms. Part I of this article will discuss how bioinformatics data is generated. It will focus on the methods used to collect this data, and the companies that support this collection.
Release: Actium Biosystems Appoints Distinguished Pharmaceutical Scientist Dr. Jessie L.-S. Au to its Scientific Advisory Board
Actium Cancer Treatment (ACT) platform’s controlled heat (hyperthermia) has the potential to substantially increase the efficacy of chemotherapy and radiation First application: non-muscle-invasive bladder cancer (NMIBC).
Atossa Genetics’ Portfolio Can Detect Breast Cancer. But Can These Products Eradicate It?
Atossa Genetics believes it can prevent breast cancer by 2020 — and in the meantime, capture a unique market opportunity — with their novel cellular and molecular diagnostic risk assessment products for early detection. Yet in a burgeoning diagnostics space, and rapid advancement in cancer therapeutics, will this company find a niche?
DelMar IPO Obscurity Could Offer Investors Favorable Entry
DelMar Pharmaceuticals (DMPI.OB) started 2013 with a revealing corporate update on January 8th. In the update, president and CEO Jeffrey Bacha outlined his goals with an exciting year ahead for the company and its employees. Mr. Bacha focused primarily on the company’s lead product candidate, VAL-083, a small molecule (chemotherapy) agent that DelMar is developing in a dose escalation trial for recurrent glioblastoma multiforme (GBM).
